

What Is Claimed Is

- sub A17
1. A method for treatment of mammals suffering from a non-pulmonary disease which comprises orally administering an effective amount of a composition of a protein, which has been stabilized so as to transgress the gastrointestinal tract, said protein being the conjugate, crosslinked or crystalline adduct of a member selected from the group consisting of alpha 1-antitrypsin, secretory leucocyte protease inhibitor and alpha 2-macroglobulin.
 2. The method of claim 1 including an antioxidant.
 3. The method of claim 2 wherein said antioxidant is selected from the group consisting of glutathione, catalase and mannitol.
 4. The method of claim 1 wherein said protein is a polyethylene glycol-alpha 1-antitrypsin adduct.
 5. The method of claim 1 wherein said protein is a polyethylene glycol-secretory leucocyte protease inhibitor adduct.
 6. The method of claim 1 wherein said protease inhibitors are crystalline.
 7. The method of claim 1 wherein said protease inhibitors are crosslinked.
 8. The method of claim 1 wherein said protease inhibitors are conjugated.
 9. The method of claim 8 wherein said protease inhibitor is alpha 1-antitrypsin conjugated with dextran or polyethylene glycol.
 10. The method of claim 1 wherein said composition includes a corticosteroid.
 11. The method of claim 1 including the step of separately administering orally a corticosteroid.

0957012-092001
T00260-2T02560

12. The method of claim 1 wherein said disease is eczema.
13. The method of claim 1 wherein said disease is interstitial cystitis.
14. The method of claim 1 wherein said disease is rheumatoid arthritis.
15. The method for treatment of mammals suffering from a disease characterized by matrix metallo-proteinases which comprises orally administering an effective amount of a composition of a protein, which has been stabilized so as to transgress the gastrointestinal tract, said protein being the conjugate, crosslinked or crystalline adduct of a member selected from the group consisting of alpha 1-antitrypsin, secretory leucocyte protease inhibitor and alpha 2-macroglobulin.
16. The method of claim 15 wherein said protein is a polyethylene glycol alpha 1-antitrypsin adduct.
17. The method of claim 15 wherein said protein is a polyethylene glycol-secretory leucocyte protease inhibitor adduct.
18. The method of claim 15 wherein said protease inhibitors are crystalline.
19. The method of claims 15 wherein said protease inhibitors are crosslinked.
20. The method of claim 15 wherein said protease inhibitors are conjugated.

Sub A
Cont'

002260 21025660